Codexis (CDXS) is Roubaix Capital’s Star Performer During the Q4 of 2020
Roubaix Capital LLC, an investment management firm, published its ‘Roubaix Fund Composite’ fourth-quarter 2020 Investor Letter – a copy of which can be downloaded here. A net return of 26.63% was recorded by the fund for the Q4 of 2020, outperforming its HFRI Equity Hedge benchmark that delivered a 14.50% return but below its Russell 2000 index that had a 31.37% return. You can view the fund’s top 5 holdings to have a peek at their top bets for 2021.
Roubaix Capital, in their Q4 2020 Investor Letter, said that Codexis, Inc. (NASDAQ: CDXS) was the top contributor for their portfolio in the fourth quarter of 2020. Codexis, Inc. is a premier protein engineering company that currently has a $1.6 billion market cap. For the past 3 months, CDXS delivered a decent 68.44% return and settled at $26.31 per share at the closing of February 12th.
Repro Med (KRMD): Top Detractor for Roubaix Capital in Q4’20
Roubaix Capital LLC, an investment management firm, published its ‘Roubaix Fund Composite’ fourth-quarter 2020 Investor Letter – a copy of which can be downloaded here. A net return of 26.63% was recorded by the fund for the Q4 of 2020, outperforming its HFRI Equity Hedge benchmark that delivered a 14.50% return but below its Russell 2000 index that had a 31.37% return. You can view the fund’s top 5 holdings to have a peek at their top bets for 2021.
Roubaix Capital, in their Q4 2020 Investor Letter, said that Repro Med Systems, Inc. (NASDAQ: KRMD) was the largest detractor for their portfolio in the fourth quarter of 2020. Repro Med Systems, Inc. is a medical device designer and manufacturing company that currently has a $192 million market cap. For the past 3 months, KRMD delivered a 9.25% return and settled at $4.37 per share at the closing of February 12th.